# FULC — Fulcrum Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** FULC  
**Sources:** 16  
**Published:** 2026-10-31  
**Canonical:** https://app.k3vl4r.com/research/deep-research-fulc-fulcrum-therapeutics-inc-catalysts-narrative-risks-10429

---

## Overview

As of the October 30, 2026 close, Fulcrum Therapeutics (NASDAQ: FULC) trades around $3.71 with a market capitalization near $283M, and the company is in the middle of a defining corporate transition: exiting its lead clinical program (pociredir) and pivoting into an all-stock merger with Slate Medicines to become a migraine-focused biotechnology business [[2]](https://finance.yahoo.com/healthcare/articles/fulcrum-fulc-allocating-95-combined-182824564.html)[[9]](https://www.marketbeat.com/earnings/reports/2026-11-4-fulcrum-therapeutics-inc-stock/). The stock has been intensely news-driven.

## Recent catalysts (last ~1–3 months, as of 2026-10-31)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-fulc-fulcrum-therapeutics-inc-catalysts-narrative-risks-10429 (free to sign up)._